Antibody against human TGF-β LAP degradate, and use thereof
US11261244B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 17, 2020 |
| Grant date | Mar 1, 2022 |
| Priority date | — |
| Expiry date | Jul 28, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed is an isolated monoclonal antibody against a human Transforming Growth Factor-β (TGF-β) Latency Associated Protein (LAP) degradate, the isolated monoclonal antibody being capable of recognizing an integrin binding site in the human TGF-β LAP degradate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.